HMOX1 and obesity disorder: Taken together, dual‐targeted induction of HO‐1 in fatty adipose and liver tissues is proven to be a promising therapeutic strategy to ameliorate obesity, insulin resistance, and steatohepatitis by lowering lipids and cytokines.